MintNeuro Secures Multi-Year Supply Deal as Motif Partnership Fast-Tracks Clinical BCI Adoption

New updates have been reported about MintNeuro.

MintNeuro has entered a multi-year strategic partnership and commercial supply agreement with Motif Neurotech that positions its neural sensing and stimulation chips at the core of Motif’s miniature brain-computer interface platform for mental health. The deal gives MintNeuro a committed pathway into pre-clinical, early clinical, and pivotal trials, with its ultra-low-power integrated circuits powering the core sensing and stimulation functions in Motif’s fully implantable devices.

The alliance embeds MintNeuro directly into one of the most advanced therapeutic BCI programs in psychiatry, providing real-world system validation and a continuous feedback loop to refine future chip generations. Under the roadmap, MintNeuro will align successive IC releases with Motif’s clinical milestones, moving from high-performance sensing to fully integrated stimulation, and enabling real-time monitoring and closed-loop neuromodulation for conditions such as treatment-resistant depression and bipolar disorder.

Motif recently secured U.S. FDA clearance to begin a clinical trial for treatment-resistant depression using its DOT implant, a device roughly the size of a blueberry that can be placed in a 20-minute outpatient procedure without exposing or touching the brain. MintNeuro’s extreme miniaturisation, high performance, and ultra-low power characteristics are key to making such form factors feasible, strengthening its position as a critical technology supplier as these therapies advance toward commercialisation.

The companies have already spent over a year moving from joint architecture design to active hardware validation, with MintNeuro chips integrated into devices used in pre-clinical work. This collaboration is expected to accelerate MintNeuro’s product development cycle, improve its ability to meet stringent regulatory and clinical requirements, and enhance its credibility with other neurotech device developers seeking scalable, chip-based platforms.

The partnership builds on U.K. ARIA-funded collaboration under the £4.7 million Brain Mesh project, which targets distributed networks of ultra-small wireless neural implants for mental health applications. Work under this program has helped MintNeuro advance its chip miniaturisation roadmap and deepen its U.K. ecosystem ties, including Motif’s decision to establish a U.K. subsidiary to work more closely with MintNeuro and other local partners on software and data science.

Founded as an Imperial College London spinout, MintNeuro is focused exclusively on semiconductor solutions for neural implants, with applications across epilepsy, movement disorders, depression, and cognitive conditions. Management frames this Motif agreement as both a validation of its technology and a signal that mental health neurotech is entering a phase where scalable IC platforms will be central to therapeutic deployment at commercial scale, potentially opening additional strategic partnerships and revenue streams as the BCI market matures.

Motif executives describe MintNeuro as a core technology partner whose chips are essential to delivering small, safe neuromodulation devices, while MintNeuro leadership highlights the value of working with a clinically ambitious BCI program to guide its technology roadmap. For MintNeuro, the arrangement combines long-term supply visibility, front-line clinical insight, and alignment with a high-profile U.S. mental health trial, giving the company leverage as payers, regulators, and investors increasingly focus on device-based psychiatric treatments. Over time, successful Motif trial outcomes could translate into recurring IC demand, higher volumes, and expanded use of MintNeuro’s modular platform across additional neuropsychiatric and neurological indications.

If Motif’s platform progresses successfully through pivotal studies and commercial launch, MintNeuro stands to benefit from a scaled deployment of its chips into therapeutic BCI systems targeting treatment-resistant mental illness. The combination of non-dilutive grant support, embedded roles in public research programs, and an anchor commercial partner may strengthen MintNeuro’s strategic positioning for future capital raises, licensing discussions, or broader industry collaborations across the emerging neural implant and BCI ecosystem.